AUTHORS
Sherif M. Badawy, MD, MS, MBA, Jungyoon Moon, MS2, Vanessa Shih, PharmD3, Christina Chamberlain, PhD4, Jing Zhao, PhD5, Amber M. Yates, MD6, Akosua Ofori7, Ciara Ringland, MS8, Carmen Petitjean, PhD9, Nirmish Shah Jr, MD10
AFFILIATIONS
1 Ann and Robert H. Lurie Children's Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
2 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
3 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
4 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
5 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
6 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
7 Vitaccess, London, United Kingdom
8 Vitaccess, London, United Kingdom
9 Vitaccess, London, United Kingdom
10 Duke University, Durham, North Carolina, United States
ABSTRACT
Introduction: Sickle cell disease (SCD) is characterized by serious acute and chronic complications, including pain crises. Treatment options remain limited, and many patients continue to experience pain crises. Claims or other healthcare encounter-based data sources and clinical trials often understate pain burden, as pain crises managed outside healthcare settings are not captured.
Here, we report results from the RAISE (Real-world Assessment of Impact of pain crises in Sickle cell disease) study. Our objective was to assess the frequency, severity, and management of patient-reported SCD pain crises and their impact on health-related quality of life (HRQoL) and daily activities.
Methods: RAISE was a 12-week, non-interventional, survey-based longitudinal study in patients with SCD. Adults (≥18 years) in the US with a confirmed SCD diagnosis who had ≥1 pain crisis within the 3 months before enrollment were eligible.
Participants entered data using the Vitaccess Real™ digital platform. Average daily pain (0–10 scale, from no pain to worst pain imaginable) and pain crisis status (Y/N) in the past 24 hours were captured via daily SMS surveys. If a pain crisis was reported, follow-up questions assessed worst pain (0–10 scale) and management location (home or healthcare system).
HRQoL and daily activities were assessed weekly via the Work Productivity and Activity Impairment Questionnaire (WPAI; higher score = worse impairment), Adult Sickle Cell Quality of Life Measurement (ASCQ-Me) Pain Impact Short Form v2.0 (lower score = worse quality of life), and Patient-Reported Outcomes Measurement Information System Physical Function Short Form 8b (PROMIS PF-SF 8b; lower score = worse physical functioning).
Pain crises, pain, and HRQoL-related patient-reported outcome (PRO) scores were summarized descriptively. HRQoL scores were reported by pain crisis status (≥1 pain crisis day vs none in the 7 days prior to each PRO assessment) and further stratified by management location among those with a reported pain crisis.
Results: A total of 95 participants were included. Survey completion rates were 78.2% for daily surveys, and 83.0% for weekly PROs. At baseline, mean (SD) age was 35.8 (9.4) years; 80.0% were female, and 59.0% had HbSS. Overall, 31.6% were employed full-time; 28.4% were unable to work due to disability. Overall, 52.6% reported currently taking hydroxyurea.
Over 12 weeks of follow-up, participants reported a mean of 22.3 (25.4) pain crisis days, with 53.7% of these days being home-managed (HM). Furthermore, 74 participants reported a mean of 2.9 (3.4) exclusively HM pain crises (mean duration of 3.9 [10.0] days), and 60 participants reported a mean of 2.2 (2.5) pain crises with at least one healthcare system-managed (HSM) pain crisis day (mean duration of 6.3 [9.4] days).
The mean average pain scores were 4.2 (2.4) for non-pain crisis days, and 6.1 (1.8) and 7.5 (1.7) for HM and HSM pain crisis days, respectively. Worst pain scores during pain crisis days were 6.4 (1.8) for HM and 7.9 (1.5) for HSM.
HRQoL was consistently worse during weeks with ≥1 pain crisis day vs weeks without any. Among those employed, WPAI work productivity loss score was worse during pain crisis vs non-pain crisis weeks (mean: 51.1 [30.4] vs 37.6 [26.2]). Mean WPAI score was 46.3 (30.1) in weeks with only HM pain crisis days and 74.4 (24.9) in weeks with HSM pain crisis days.
ASCQ-Me Pain Impact T-score was worse during pain crisis vs non-pain crisis weeks (mean: 44.0 [7.2] vs 48.7 [7.4]). Mean ASCQ-Me Pain Impact score was 45.5 (7.4) in weeks with only HM pain crisis days and 39.7 (6.4) in weeks that included HSM pain crisis days.
PROMIS PF-SF 8b T-score was also worse during pain crisis vs non-pain crisis weeks (mean: 37.8 [6.1] vs 39.7 [6.1]). Mean PROMIS PF-SF 8b score was 38.3 (5.5) in weeks with only HM pain crisis days and 35.2 (6.1) in weeks with HSM pain crisis days.
Conclusion: Participants reported frequent pain crises on over a quarter of study days, often exclusively managed at home without healthcare encounters. Pain intensity was high during pain crisis days, with only modest differences between HM and HSM days. HRQoL and daily activities were impaired during pain crises, regardless of management location. These findings indicate a substantial burden of pain crises beyond what is observed in healthcare settings and suggest that reliance on healthcare-based definitions of pain crises may underestimate the impact of SCD on patients.
DISCLOSURES
Sherif M. Badawy, MD, MS, MBA: X4 Therapeutics - Consultancy (Includes expert testimony); Vertex Pharmaceuticals - Consultancy (Includes expert testimony); Beam Therapeutics - Consultancy (Includes expert testimony); Editas Medicine - Consultancy (Includes expert testimony); Chiesi Pharmaceuticals - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Agios Pharmaceuticals, Inc. - Consultancy (Includes expert testimony)